Dr Reddys Laboratories Ltd
Dr Reddys Laboratories Q2 FY26: Capex ₹511 Cr
Q2 FY26 earnings call: what management said on revenue, margins and capex.
The short version
India business: Expect continued volume and price growth; price increase around 5%, rest driven by new products and volume expansion (Page 20). The company expects to maintain double-digit growth in ex-US markets over the next 1-2 years, driven by new launches, acquisitions, and innovation efforts.
From Dr Reddys Laboratories Ltd's Q2 FY26 earnings-call transcript · updated 16 Oct 2026.
Revenue & Sales Performance
- India business: Expect continued volume and price growth; price increase around 5%, rest driven by new products and volume expansion (Page 20).
- Emerging Markets & Europe: Sustained double-digit growth expected, driven by new product launches, biosimilars (Rituximab, Denosumab, Bevacizumab), NRT integration and generic injectables (Pages 14, 18).
- Semaglutide sales: Current capacity planned at 12 million pens with potential to grow to 15 million or more by 2027, especially post FTO-11 capacity ramp-up in H2 2027 (Pages 12, 20).
2 more points from Dr Reddys Laboratories Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
Read what Dr Reddys Laboratories Ltd said on margins in the Q2 FY26 call
Free account with your mobile number. We text a one-time code, no password.
Capital Expenditure Plans
- Ongoing investment in in-house fill-and-finish capacity for Semaglutide at FTO-11, including two cartridge lines capable of scaling theoretically up to 50 million pens (post next 12 months).
- Investment in API manufacturing for peptides (e.g., Semaglutide, Liraglutide) at CTO-6 with a potential capacity of up to 800 kg, supporting multiple peptide products.
- Capex cash outflow of ₹511 crores ($58 million) was incurred in Q2FY26, indicating ongoing capital expenditures.
- Strategic use of a CMO in the United States for Abatacept to mitigate regulatory and capacity risks.
- Continued focus on investments in R&D (~7% of sales) primarily for biosimilars and complex generics.
2 more points from Dr Reddys Laboratories Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Order Book & Pipeline
See what Dr Reddys Laboratories Ltd said on order book & pipeline — free account, 30 seconds.
Dr Reddys Laboratories Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹7.5K Cr, net profit ₹221 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Dr Reddys Laboratories Ltd's management said in earlier quarters
- Q2 FY27 earnings call analysis →
- Q1 FY27 earnings call analysis →
- Q1 FY26 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q4 FY25 earnings call →
- Q3 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Bajaj Healthcare Ltd (Q2 FY26)
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p
- Wanbury (Q2 FY26)
Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against
- Balaxi Pharmaceuticals Ltd (Q2 FY26)
Revenue for Q2 FY26: ₹56.17 crore . Key investor presentation takeaways from Balaxi Pharma's Q2 FY26 investor presentation — and how it ranks against sector pee
- Emcure Pharmaceuticals Ltd (Q2 FY26)
Emcure Pharmaceuticals delivered a strong Q2 FY26 with 25% PAT growth, reporting highest quarterly profit of INR 251 crores. Key concall takeaways from Emcure…
Arthneeti Pro · Annual
Dr Reddys Laboratories Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Dr Reddys Laboratories Ltd Q2 FY26 results?
India business: Expect continued volume and price growth; price increase around 5%, rest driven by new products and volume expansion (Page 20). The company expects to maintain double-digit growth in ex-US markets over the next 1-2 years, driven by new launches, acquisitions, and innovation efforts.
What is Dr Reddys Laboratories Ltd share price analysis?
Dr Reddys Laboratories Ltd currently shows a neutral. The stock trades at a P/E of 31.9 with a market cap of ₹102,899 Cr. Investors should review the full earnings analysis for detailed insights.
Is Dr Reddys Laboratories Ltd planning capital expenditure?
Ongoing investment in in-house fill-and-finish capacity for Semaglutide at FTO-11, including two cartridge lines capable of scaling theoretically up to 50 million pens (post next 12 months).
Keep Dr Reddys Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.